Liquid Biopsy Test Cleared for Use in CML
The U.S. Food and Drug Administration approved the QXDx AutoDG ddPCR System, a liquid biopsy test designed to precisely and reproducibly monitor molecular response...
Combination of Ibrutinib and Nivolumab Appears Similar to Single-Agent Therapy in Early-Phase Trial
According to results from a phase I/II trial published in Lancet Haematology, treatment with a combination of ibrutinib and the checkpoint inhibitor nivolumab was...
Ibrutinib Plus Obinutuzumab Superior to Standard Chemoimmunotherapy in Treatment-Naïve Chronic Lymphocytic Leukemia
Treatment with the regimen of ibrutinib plus obinutuzumab improved outcomes for patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL),...
For Older Patients With CLL, Ibrutinib-Based Treatment Beats Standard Chemoimmunotherapy
Results from a randomized phase III study indicate that the Bruton tyrosine kinase (BTK) inhibitor ibrutinib with or without rituximab was superior to standard-of-care,...
Duvelisib Bests Ofatumumab in Relapsed and Refractory CLL/SLL
In the phase III DUO trial, treatment with the oral phosphoinositide 3-kinase (PI3K) dual inhibitor duvelisib improved progression-free survival (PFS) and overall response, compared...
Ibrutinib Versus FCR: A “Paradigm Shift” for Younger Patients With Treatment-Naïve CLL
In patients with previously untreated chronic lymphocytic leukemia (CLL), treatment with an ibrutinib-based therapy improved progression-free survival (PFS) and overall survival (OS), compared with...
Weighing Conditioning Regimens for Patients With CML Undergoing Transplant
Conditioning with a reduced-intensity, nonmyeloablative regimen was associated with similar post-transplant survival but a lower risk of chronic graft-versus-host disease (cGVHD), compared with a...
Higher Childhood Leukemia Risk in Offspring Raises Questions About Hormonal Contraceptive Safety
Children born to women who were using hormonal contraception within three months of pregnancy and during pregnancy have a higher risk of developing myeloid...
How I Treat In Brief: Managing Ibrutinib-Refractory Chronic Lymphocytic Leukemia
Jennifer A. Woyach, MD, associate professor at the Ohio State University Comprehensive Cancer Center, wrote about her strategy for the management of patients with...
Demystifying Epigenetics in Hematology
In the early 20th century, German researcher Theodor Boveri described the basic tenets of tumor biology: Cells can turn cancerous when they lose the...
Current Issue
December 2019, Volume 5, Issue 15
This issue examines the hidden costs of participating in clinical trials, explores the pediatric hematology/oncology workforce, and more.
